124 related articles for article (PubMed ID: 8790200)
1. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Meredith RF; Partridge EE; Alvarez RD; Khazaeli MB; Plott G; Russell CD; Wheeler RH; Liu T; Grizzle WE; Schlom J; LoBuglio AF
J Nucl Med; 1996 Sep; 37(9):1491-6. PubMed ID: 8790200
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Alvarez RD; Partridge EE; Khazaeli MB; Plott G; Austin M; Kilgore L; Russell CD; Liu T; Grizzle WE; Schlom J; LoBuglio AF; Meredith RF
Gynecol Oncol; 1997 Apr; 65(1):94-101. PubMed ID: 9103398
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
[TBL] [Abstract][Full Text] [Related]
4. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
7. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
Cederkrantz E; Andersson H; Bernhardt P; Bäck T; Hultborn R; Jacobsson L; Jensen H; Lindegren S; Ljungberg M; Magnander T; Palm S; Albertsson P
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):569-76. PubMed ID: 26460999
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
Meredith RF; Bueschen AJ; Khazaeli MB; Plott WE; Grizzle WE; Wheeler RH; Schlom J; Russell CD; Liu T; LoBuglio AF
J Nucl Med; 1994 Jun; 35(6):1017-22. PubMed ID: 8195861
[TBL] [Abstract][Full Text] [Related]
9. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
10. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Miller LS; Houchens D; Cheng R; Kaplan D; Goeckeler W
Cancer Res; 1991 Jun; 51(11):2889-96. PubMed ID: 1851665
[TBL] [Abstract][Full Text] [Related]
14. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith RF; Buchsbaum DJ; Alvarez RD; LoBuglio AF
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5643s-5645s. PubMed ID: 17875801
[TBL] [Abstract][Full Text] [Related]
15. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Vallabhajosula S; Goldsmith SJ; Kostakoglu L; Milowsky MI; Nanus DM; Bander NH
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
[TBL] [Abstract][Full Text] [Related]
17. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
18. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
Breitz HB; Durham JS; Fisher DR; Weiden PL
Cancer Res; 1995 Dec; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal α-Emitting Radioimmunotherapy with
Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
